Vexev
AI-powered robotic ultrasound that lets non-specialists capture vascular scans at the point of care.
Private company- Sector
- Healthtech
- Based in
- Sydney, Australia
- Founded
- 2018
- Invested
- Jun 2026
Vexev is developing VxWave, a robotic ultrasound system for imaging blood vessels in the arm. It combines robotics, machine learning and ultrasound signal processing to scan the limb automatically and produce a 3D model of the vessels with a report, so that clinical staff without specialist sonography training can get usable vascular images.
Its first application is mapping arteriovenous fistulas for dialysis patients. In a 120-patient trial with U.S. Renal Care, results announced in late 2025 showed a 94% scanning success rate with non-specialist staff operating the system. VxWave is for investigational use only and is not yet cleared for sale by the FDA or other regulators. In August 2026 the company raised a further $6 million towards FDA clearance, manufacturing and a US launch.
Vexev was founded in Sydney in 2018 by Dr Eamonn Colley and Dr John Carroll, and operates in Australia and the United States.
As of 29 Sep 2026
Why I own it
Robotics and AI are coming to healthcare. Vexev's robotic ultrasound lets someone without specialist training capture a vascular scan, starting with dialysis patients who need them often.
Skilled sonographers are scarce and expensive. A robot that brings the scan to the bedside, guided by AI, is the kind of physical AI I think will spread through medicine.
Then · Jun 2026
Since I invested
- Held for
- 4 months
- Status
- Active
